Cargando…

Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer

Complete pathological response to neoadjuvant systemic treatment (NAST) in some subtypes of breast cancer (BC) has been used as a surrogate of long-term outcome. The possibility of predicting BC pathological response to NAST based on the baseline 18F-Fluorodeoxyglucose positron emission tomography (...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Carla, Oliveira, Francisco, Vaz, Sofia C., Marques, Hugo Pinto, Cardoso, Fátima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Institute of Radiology. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230392/
https://www.ncbi.nlm.nih.gov/pubmed/36867773
http://dx.doi.org/10.1259/bjr.20220655
_version_ 1785051517464608768
author Oliveira, Carla
Oliveira, Francisco
Vaz, Sofia C.
Marques, Hugo Pinto
Cardoso, Fátima
author_facet Oliveira, Carla
Oliveira, Francisco
Vaz, Sofia C.
Marques, Hugo Pinto
Cardoso, Fátima
author_sort Oliveira, Carla
collection PubMed
description Complete pathological response to neoadjuvant systemic treatment (NAST) in some subtypes of breast cancer (BC) has been used as a surrogate of long-term outcome. The possibility of predicting BC pathological response to NAST based on the baseline 18F-Fluorodeoxyglucose positron emission tomography (FDG PET), without the need of an interim study, is a focus of recent discussion. This review summarises the characteristics and results of the available studies regarding the potential impact of heterogeneity features of the primary tumour burden on baseline FDG PET in predicting pathological response to NAST in BC patients. Literature search was conducted on PubMed database and relevant data from each selected study were collected. A total of 13 studies were eligible for inclusion, all of them published over the last 5 years. Eight out of 13 analysed studies indicated an association between FDG PET-based tumour uptake heterogeneity features and prediction of response to NAST. When features associated with predicting response to NAST were derived, these varied between studies. Therefore, definitive reproducible findings across series were difficult to establish. This lack of consensus may reflect the heterogeneity and low number of included series. The clinical relevance of this topic justifies further investigation about the predictive role of baseline FDG PET.
format Online
Article
Text
id pubmed-10230392
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The British Institute of Radiology.
record_format MEDLINE/PubMed
spelling pubmed-102303922023-06-01 Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer Oliveira, Carla Oliveira, Francisco Vaz, Sofia C. Marques, Hugo Pinto Cardoso, Fátima Br J Radiol Review Article Complete pathological response to neoadjuvant systemic treatment (NAST) in some subtypes of breast cancer (BC) has been used as a surrogate of long-term outcome. The possibility of predicting BC pathological response to NAST based on the baseline 18F-Fluorodeoxyglucose positron emission tomography (FDG PET), without the need of an interim study, is a focus of recent discussion. This review summarises the characteristics and results of the available studies regarding the potential impact of heterogeneity features of the primary tumour burden on baseline FDG PET in predicting pathological response to NAST in BC patients. Literature search was conducted on PubMed database and relevant data from each selected study were collected. A total of 13 studies were eligible for inclusion, all of them published over the last 5 years. Eight out of 13 analysed studies indicated an association between FDG PET-based tumour uptake heterogeneity features and prediction of response to NAST. When features associated with predicting response to NAST were derived, these varied between studies. Therefore, definitive reproducible findings across series were difficult to establish. This lack of consensus may reflect the heterogeneity and low number of included series. The clinical relevance of this topic justifies further investigation about the predictive role of baseline FDG PET. The British Institute of Radiology. 2023-06-01 2023-03-03 /pmc/articles/PMC10230392/ /pubmed/36867773 http://dx.doi.org/10.1259/bjr.20220655 Text en © 2023 The Authors. Published by the British Institute of Radiology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 Unported License http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial reuse, provided the original author and source are credited.
spellingShingle Review Article
Oliveira, Carla
Oliveira, Francisco
Vaz, Sofia C.
Marques, Hugo Pinto
Cardoso, Fátima
Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer
title Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer
title_full Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer
title_fullStr Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer
title_full_unstemmed Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer
title_short Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer
title_sort prediction of pathological response after neoadjuvant chemotherapy using baseline fdg pet heterogeneity features in breast cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230392/
https://www.ncbi.nlm.nih.gov/pubmed/36867773
http://dx.doi.org/10.1259/bjr.20220655
work_keys_str_mv AT oliveiracarla predictionofpathologicalresponseafterneoadjuvantchemotherapyusingbaselinefdgpetheterogeneityfeaturesinbreastcancer
AT oliveirafrancisco predictionofpathologicalresponseafterneoadjuvantchemotherapyusingbaselinefdgpetheterogeneityfeaturesinbreastcancer
AT vazsofiac predictionofpathologicalresponseafterneoadjuvantchemotherapyusingbaselinefdgpetheterogeneityfeaturesinbreastcancer
AT marqueshugopinto predictionofpathologicalresponseafterneoadjuvantchemotherapyusingbaselinefdgpetheterogeneityfeaturesinbreastcancer
AT cardosofatima predictionofpathologicalresponseafterneoadjuvantchemotherapyusingbaselinefdgpetheterogeneityfeaturesinbreastcancer